This paper is only available as a PDF. To read, Please Download here.
Abstract
A subcutaneous contraceptive capsule releasing progestin ST-1435 was used by 6 breast-feeding
women. One to three paired milk and plasma samples were collected over a one-month
period and the concentrations of ST-1435 were determined by radioimmunoassay.
An improved and sensitive method for determination of ST-1435 in milk was developed.
A column chromatographic purification of milk prior to radioimmunoassay decreased
the blank and improved sensitivity.
The average plasma concentration of ST-1435 was 62 ± 20 pg/ml (mean ± SD). The average milk concentration of ST-1435 was 38 pg/ml (ranging from 7 to 73 pg/ml),
while the average milk to plasma ratio was 0.60 (ranging from 0.25 to 0.91). There
was a significant correlation between ST-1435 concentrations in breast milk and plasma,
indicating that the concentration in plasma is the major determinant for the amount
of ST-1435 excreted into milk. Since studies with this drug have shown good contraceptive
efficacy and low bioavailability after oral intake, ST-1435 is a good candidate for
lactational contraception.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Editorial.in: International Conference on better health for women and children through family planning: recommendations for action. Stud in Fam Plann. 19. 1988: 58-60
- D-norgestrel concentrations in maternal plasma, milk and child plasma during administration of oral contraceptives to nursing women.Am J Obstet Gynecol. 1977; 129: 178-184
- Transfer of contraceptive steroids in milk of women using long-lasting gestagens.Contraception. 1982; 25: 321-331
- Intestinal absorption of ST-1435 in rats.Contraception. 1984; 30: 143-151
- Fertility control with subdermal Silastic capsules containing a new progestin (ST-1435).Int J Fertil. 1976; 21: 103-108
- Contraception with subcutaneous capsules containing ST-1435.Contraception. 1981; 23: 63-75
- Pituitary and ovarian function during contraception with one subcutaneous implant releasing a progestin, ST-1435.Contraception. 1984; 29: 299-306
- Intracervical release of ST-1435 for contraception.Contraception. 1984; 29: 411-421
- Concentration-dependent mechanisms of ovulation inhibition by the progestin ST-1435.Fertil Steril. 1985; 44: 20-24
- Contraception with subdermal ST-1435 capsules: side-effects, endocrine profiles and liver function related to different lengths of capsules.Contraception. 1985; 31: 305-318
- Effects of progestins on lipoprotein patterns.in: Bardin CW Milgrom E Mauvais-Jarvis P Progesterone and progestins. Raven Press, New York1983: 421-432
- Serum non-protein bound percentage and distribution of the progestin ST-1435: no effect of ST-1435 treatment on plasma SHBG and CBG binding capacities.Acta Endocrinologica (Kbh.). 1983; 102: 307-313
- Contraceptive action of a synthetic progestin, ST-1435.in: Academic Dissertation. University of Helsinki, Helsinki, Finland1986
- Column chromatography of steroids on Sephadex LH-20.J Clin Endocrinol. 1971; 33: 358-360
- Levonorgestrel in milk and plasma of breast-feeding women with a levonorgestrel-releasing IUD.Contraception. 1982; 25: 41-49
- Distribution and percentages of non-protein bound contraceptive steroids in human serum.J Steroid Biochem. 1982; 17: 375-380
Article info
Publication history
Accepted:
September 6,
1990
Received:
May 1,
1990
Identification
Copyright
© 1990 Published by Elsevier Inc.
